

**IN THE UNITED STATES DISTRICT COURT
FOR DELAWARE**

ASTRAZENECA PHARMACEUTICALS
LP,

and

ASTRAZENECA UK LIMITED,

and

IPR PHARMACEUTICALS, INC.,

and

SHIONOGI SEIYAKU KABUSHIKI
KAISHA,

Plaintiffs,

v.

SANDOZ INC.,

Defendant.

Civil Action No.: _____

COMPLAINT FOR PATENT INFRINGEMENT

Plaintiffs, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, IPR
Pharmaceuticals, Inc., and Shionogi Seiyaku Kabushiki Kaisha, for their Complaint against
Sandoz Inc., hereby state as follows:

Nature of the Action

1. This is a civil action for patent infringement arising under the patent laws of the
United States, 35 U.S.C. § 100 et seq., and in particular under 35 U.S.C. §§ 271(e) and (a). This
action relates to an Abbreviated New Drug Application (“ANDA”) filed by Sandoz Inc. (“the
Sandoz ANDA”) with the United States Food and Drug Administration (“FDA”) for approval to

market generic versions of Plaintiffs' highly successful Crestor[®] pharmaceutical products that are sold in the United States.

Parties

2. Plaintiff AstraZeneca Pharmaceuticals LP ("AstraZeneca") is a corporation operating and existing under the laws of Delaware with its principal place of business at 1800 Concord Pike, Wilmington, Delaware 19803 USA.

3. Plaintiff AstraZeneca UK Limited is a corporation operating and existing under the laws of the United Kingdom with its principal place of business at 15 Stanhope Gate, London W1K 1LN, England.

4. Plaintiff IPR Pharmaceuticals, Inc. ("IPR") is a corporation operating and existing under the laws of Puerto Rico with its principal place of business at Carr 188 Lote 17, San Isidro Industrial Park, Canovanas, Puerto Rico 00729.

5. Plaintiff Shionogi Seiyaku Kabushiki Kaisha is a corporation operating and existing under the laws of Japan with its principal place of business at 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045 Japan.

6. Defendant Sandoz Inc. ("Sandoz") represented in its letter notifying Plaintiffs of the Sandoz ANDA and the certifications made to the FDA regarding Plaintiffs' patents that it is a corporation operating and existing under the laws of Delaware with its principal place of business at 506 Carnegie Center, Suite 400, Princeton, New Jersey 08540 USA.

Background

7. IPR is the holder of approved New Drug Application (“NDA”) No. 021366 for Crestor[®] Tablets, in 5 mg, 10 mg, 20 mg, and 40 mg dosage forms, containing rosuvastatin calcium. AstraZeneca is IPR’s authorized agent for matters related to NDA No. 021366.

8. CRESTOR[®] (rosuvastatin calcium) is a prescription drug belonging to a group of medicines (called statins) that are used to treat high cholesterol. Crestor[®] is one of the most effective lipid-lowering statins available. Over 11 million patients have been prescribed Crestor[®], and over 110 million prescriptions have been written worldwide for Crestor[®].

9. Plaintiffs, among other things, manufacture, market, promote, educate the public and physicians about, and conduct research and development on existing and new indications for Crestor[®] Tablets. Plaintiffs financially benefit from sales of Crestor[®] Tablets in the United States.

10. On information and belief, Sandoz filed with the FDA, in Rockville, Maryland, ANDA No. 79-171 under 21 U.S.C. § 355(j) to obtain FDA approval for the commercial manufacture, use, importation, offer for sale, and sale in the United States of rosuvastatin calcium tablets in 5 mg, 10 mg, 20 mg, and 40 mg dosage strengths, which are generic versions of Plaintiffs’ Crestor[®] Tablets in 5 mg, 10 mg, 20 mg, and 40 mg dosage strengths, respectively.

11. By letter dated November 8, 2007, Sandoz notified Plaintiffs that it had filed an ANDA seeking FDA approval to market rosuvastatin calcium tablets in 5 mg, 10 mg, 20 mg, and 40 mg dosage strengths (hereinafter referred to as “the Sandoz Rosuvastatin Calcium Tablets”),

and that it was providing information to Plaintiffs pursuant to 21 U.S.C. § 355(j)(2)(B)(i), (ii), (iii), and (iv).

12. On information and belief, Sandoz is in the business of developing and manufacturing generic pharmaceutical products. On information and belief, Sandoz markets, distributes, and sells generic pharmaceutical products throughout the United States, including the State of Delaware.

Jurisdiction and Venue

13. Subject matter jurisdiction is proper under 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

14. Personal jurisdiction over Sandoz is proper because Sandoz is incorporated in Delaware and has purposely availed itself of the privilege of doing business in this State. Further, Sandoz maintains continuous and systematic contacts with the State of Delaware so as to reasonably allow jurisdiction to be exercised over it.

15. Venue is proper in this judicial district under 28 U.S.C. §§ 1391(c) and 1400(b).

Count I

Infringement of United States Patent No. RE37,314 Under 35 U.S.C. § 271(e)(2)

16. Plaintiffs incorporate by reference paragraphs 1-15 of this Complaint as if fully set forth herein.

17. United States Patent No. RE37,314 (“the ‘314 patent”), entitled “Pyrimidine Derivatives,” was duly and legally reissued by the United States Patent and Trademark Office on

August 7, 2001. Plaintiffs hold all substantial rights in the '314 patent and have the right to sue for infringement thereof. A true and correct copy of the '314 patent is attached as Exhibit A.

18. On information and belief, Sandoz filed ANDA No. 79-171 in order to obtain approval to market the Sandoz Rosuvastatin Calcium Tablets in the United States before the expiration of the '314 patent. On information and belief, Sandoz also filed with the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) and 21 C.F.R. § 314.94(a)(12)(i)(A)(4), a certification alleging that the claims of the '314 patent are invalid and that the '314 patent is unenforceable.

19. On information and belief, Sandoz does not assert that Sandoz Rosuvastatin Calcium Tablets are not covered by one or more claims of the '314 patent.

20. Under 35 U.S.C. § 271(e)(2)(A), the submission by Sandoz to the FDA of ANDA No. 79-171 to obtain approval for the commercial manufacture, use, or sale of the Sandoz Rosuvastatin Calcium Tablets before the expiration date of the '314 patent constitutes infringement of one or more claims of the '314 patent, either literally or under the doctrine of equivalents.

21. Plaintiffs will be substantially and irreparably harmed by the infringing activities described above unless those activities are precluded by this Court. Plaintiffs have no adequate remedy at law.

Count II

Declaratory Judgment of Infringement of United States Patent No. RE37,314
Under 35 U.S.C. § 271(a)

22. Plaintiffs incorporate by reference paragraphs 1-21 of this Complaint as if fully set forth herein.

23. Upon information and belief, Sandoz has made substantial preparations to sell Sandoz Rosuvastatin Calcium Tablets labeled for the same dosages as the Crestor[®] products.

24. Upon information and belief, Sandoz intends to commence sale of Sandoz Rosuvastatin Calcium Tablets immediately upon receiving approval from the FDA.

25. The manufacture, importation, sale, and offer for sale of Sandoz Rosuvastatin Calcium Tablets, once approved by the FDA, will directly infringe, induce and/or contribute to the infringement of one or more claims of the '314 patent under 35 U.S.C. § 271(a).

26. Plaintiffs will be substantially and irreparably harmed by the infringing activities described above unless those activities are enjoined by this Court. Plaintiffs have no adequate remedy at law.

27. An actual controversy exists relating to Cobalt's threatened infringement of the '314 patent.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in its favor as follows:

- (1) holding that the claims of the '314 patent are valid and enforceable;

(2) holding that the submission of ANDA No. 79-171 by Sandoz infringes one or more claims of the '314 patent under 35 U.S.C. § 271(e)(2);

(3) declaring that the manufacture, use, offering for sale, or sale of the Sandoz Rosuvastatin Calcium Tablets within the United States or importing the Sandoz Rosuvastatin Calcium Tablets into the United States before expiration of the '314 patent will infringe one or more claims of the '314 patent;

(4) ordering, pursuant to 35 U.S.C. § 271(e)(4)(A), that the effective date of any FDA approval of the Sandoz Rosuvastatin Calcium Tablets shall be no earlier than the expiration date of the '314 patent;

(5) enjoining Sandoz, and all persons acting in concert with Sandoz, from commercially manufacturing, using, offering for sale, or selling the Sandoz Rosuvastatin Calcium Tablets within the United States or importing into the United States the Sandoz Rosuvastatin Calcium Tablets, prior to the expiration of the '314 patent;


(6) declaring this to be an exceptional case and awarding Plaintiffs their attorney fees under 35 U.S.C. § 285;

(7) awarding Plaintiffs their costs and expenses in this action; and

(8) awarding Plaintiffs any further and additional relief as this Court deems just and proper.

This 11th day of December 2007.

Respectfully submitted,



Mary W. Bourke (#2356)
CONNOLLY BOVE LODGE & HUTZ LLP
1007 N. Orange Street
Wilmington, DE 19899
Telephone: (302) 658-9141
Facsimile: (302) 658-5614
mbourke@cblh.com

Of Counsel:

Ford F. Farabow
Charlie E. Lipsey
York M. Faulkner
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001
Telephone: (202) 408-4000
Facsimile: (202) 408-4400

Henry J. Renk
FITPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, NY 10112
Telephone: (212) 218-2100
Facsimile: (212) 218-2200

*Attorneys for Plaintiffs,
AstraZeneca Pharmaceuticals LP, AstraZeneca UK
Limited, IPR Pharmaceuticals, Inc., and Shionogi
Seiyaku Kabushiki Kaisha*